摘要
目的观察慢性心力衰竭患者缬沙坦治疗前后血浆脑钠肽的变化,探讨缬沙坦对心室重构的影响。方法55例慢性心力衰竭患者,随机分为缬沙坦治疗组(n=25)和常规治疗组(对照组,n=30),缬沙坦组除常规抗心衰治疗外加用缬沙坦40～80mg/d,在治疗前、治疗后2周、治疗后1个月、治疗后3个月不同时间采静脉血测定BNP值,治疗前和治疗后3个月超声心动图测定心功能和心室重构指标。结果缬沙坦组和对照组治疗后血浆BNP水平较治疗前均有下降,但缬沙坦组下降得更明显,两组比较差异有统计学意义(P<0.01);治疗后3个月时,左室射血分数、左室收缩末内径、左室舒张末内径两组之间差异无统计学意义,但左室后壁厚度、室间隔厚度和左室重量指数缬沙坦组显著低于对照组(P<0.05)。结论缬沙坦可显著抑制心衰患者BNP的分泌和心室重构,改善心功能。
Objective To observe the level of plasma brain natriuretie peptide （BNP） before and after administration of valsartan , and study the effect of the drug on ventricle remodeling. Methods Fifty - five patients with chronic congestive heart failure（CHF） were divided into valsartan group and conventional treament group（ control group）. The valsartan group was given valsartan 40 - 80 mg/day in addition to conventional treatment. The level of BNP was analysed before treatment, and the second week, the first month and the third month after treatment. Results The levels of BNP decreased in both groups after treatment, but more apparently in valsartan group. On the third month, the differences in LVEF, LVESD, and LVEDD between the two groups were not significant, but LVPWD, IVSD and LVMI in valsartan group were much lower than in the control group. Conclusions Valsartan inhibits the secretion of BNP and the remodeling of ventricle in CHF patients, and ameliorates the heart function.
出处
《武警医学》
CAS
2005年第8期588-591,共4页
Medical Journal of the Chinese People's Armed Police Force
